Replimune Group, Inc. (REPL)
8.07
+1.03
(+14.63%)
USD |
NASDAQ |
Mar 06, 16:00
9.21
+1.14
(+14.13%)
After-Hours: 20:00
Replimune Group Cash from Investing (Quarterly) : 75.12M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Catalyst Pharmaceuticals, Inc. | -0.032M |
| Sarepta Therapeutics, Inc. | 96.21M |
| REGENXBIO, Inc. | 37.54M |
| Bristol Myers Squibb Co. | -1.458B |
| Mirum Pharmaceuticals, Inc. | 1.006M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -65.96M |
| Cash from Financing (Quarterly) | 10.45M |
| Free Cash Flow | -283.27M |
| Free Cash Flow Per Share (Quarterly) | -0.7169 |
| Free Cash Flow to Equity (Quarterly) | -66.11M |
| Free Cash Flow to Firm (Quarterly) | -64.13M |
| Free Cash Flow Yield | -39.81% |